8-K: Aethlon Medical Announces 1-for-8 Reverse Stock Split to Take Effect June 6, 2025

Aethlon Medical, Inc. has announced a 1-for-8 reverse stock split of its common stock, effective June 6, 2025, with split-adjusted trading to commence on Nasdaq on June 9, 2025.

Summary

• Aethlon Medical, Inc. (AEMD) announced a 1-for-8 reverse stock split of its common stock.
• The reverse stock split was initially approved by stockholders on May 13, 2025, with a flexible ratio range of 1-for-5 to 1-for-12.
• Following the stockholder approval, the Board of Directors unanimously approved the specific 1-for-8 ratio for the Reverse Stock Split.
• The Reverse Stock Split will become effective at 5:00 p.m. Eastern Time on June 6, 2025.
• Trading of the company's common stock on a split-adjusted basis will begin upon market opening on The Nasdaq Capital Market on June 9, 2025.
• Under the terms, every eight shares of the company's issued and outstanding common stock will automatically be combined into one issued and outstanding share, without any change in the par value of $0.001 per share.
• Proportionate adjustments will be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock units, and warrants.
• The number of shares reserved for issuance under the company's equity compensation plans immediately prior to the effective time will also be reduced proportionately.
• No fractional shares will be issued; stockholders will receive one whole share of common stock in exchange for any fractional interest they would have otherwise received.
• The Reverse Stock Split will affect all stockholders proportionately and will not affect any stockholder's percentage ownership of the company's common stock, except for the minor adjustment related to fractional shares.
• The new CUSIP number for the company's common stock following the Reverse Stock Split is 00808Y 505.

Sentiment

Score: 5

Explanation: The reverse stock split is a corporate action primarily aimed at increasing the per-share price, likely to maintain Nasdaq listing compliance. While it addresses a technical requirement, it does not inherently improve the company's fundamental business performance or financial health. The document is factual regarding the split mechanics and does not present explicit negatives.

Positives

• The company will issue one whole share of common stock in exchange for any fractional interest, preventing stockholders from losing value on fractional shares.
• The reverse stock split will not affect any stockholder's percentage ownership of the company's common stock, ensuring proportional equity remains intact.

Future Outlook

The document focuses solely on the mechanics and implementation of the reverse stock split and does not provide any forward-looking statements or guidance regarding the company's future business performance or strategic outlook.

Management Comments

• The report was duly caused to be signed on behalf of the registrant by James B. Frakes, Chief Executive Officer and Chief Financial Officer.

Industry Context

This document details a specific corporate action by Aethlon Medical, Inc. and does not provide information on broader industry trends or the competitive landscape. Reverse stock splits are common actions taken by companies to increase their per-share stock price, often to meet minimum bid price requirements for continued listing on exchanges like Nasdaq.

Corporate Governance

Stakeholder Impact

• Shareholders: The number of shares held will decrease by a factor of eight, but their percentage ownership will remain unchanged (except for minor adjustments due to fractional shares being rounded up). The per-share price is expected to increase proportionally.
• Option/Warrant Holders: Exercise prices will increase and the number of shares issuable upon exercise will decrease proportionally, maintaining the overall value of their holdings.

Next Steps

• The Reverse Stock Split will be implemented at 5:00 p.m. Eastern Time on June 6, 2025.
• The Company's common stock will begin trading on a split-adjusted basis commencing upon market opening on The Nasdaq Capital Market on June 9, 2025.

Key Dates

Recommendation

Keywords

Aethlon Medical, AEMD, reverse stock split, common stock, Nasdaq Capital Market, corporate action, SEC filing, 8-K, stock options, warrants, restricted stock units